Quality and Timing of Stressors Differentially Impact on Brain Plasticity and Neuroendocrine-Immune Function in Mice by Capoccia, Sara et al.
Hindawi Publishing Corporation
Neural Plasticity
Volume 2013, Article ID 971817, 8 pages
http://dx.doi.org/10.1155/2013/971817
Research Article
Quality and Timing of Stressors Differentially Impact on Brain
Plasticity and Neuroendocrine-Immune Function in Mice
Sara Capoccia,1 Alessandra Berry,1 Veronica Bellisario,1 Davide Vacirca,2 Elena Ortona,2
Enrico Alleva,1 and Francesca Cirulli1
1 Section of Behavioural Neuroscience, Department of Cell Biology and Neurosciences, Istituto Superiore di Sanita`,
Viale Regina Elena 299, 00161 Rome, Italy
2 Section of Biomarkers in Degenerative Diseases, Department of Cell Biology and Neurosciences, Istituto Superiore di Sanita`,
Viale Regina Elena 299, 00161 Rome, Italy
Correspondence should be addressed to Francesca Cirulli; francesca.cirulli@iss.it
Received 23 January 2013; Revised 8 March 2013; Accepted 12 March 2013
Academic Editor: Alessandro Sale
Copyright © 2013 Sara Capoccia et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
A growing body of evidence suggests that psychological stress is a major risk factor for psychiatric disorders.The basic mechanisms
are still under investigation but involve changes in neuroendocrine-immune interactions, ultimately affecting brain plasticity. In this
study we characterized central and peripheral effects of different stressors, applied for different time lengths, in adult male C57BL/6J
mice. We compared the effects of repeated (7 versus 21 days) restraint stress (RS) and chronic disruption of social hierarchy (SS)
on neuroendocrine (corticosterone) and immune function (cytokines and splenic apoptosis) and on a marker of brain plasticity
(brain-derived neurotrophic factor, BDNF ). Neuroendocrine activation did not differ between SS and control subjects; by contrast,
the RS group showed a strong neuroendocrine response characterized by a specific time-dependent profile. Immune function
and hippocampal BDNF levels were inversely related to hypothalamic-pituitary-adrenal axis activation. These data show a fine
modulation of the crosstalk between central and peripheral pathways of adaptation and plasticity and suggest that the length of
stress exposure is crucial to determine its final outcome on health or disease.
1. Introduction
Stressful events are well-known risk factors that can promote
neurochemical changes ultimately involved in the pathophys-
iology of psychiatric disorders such asmajor depression [1–3].
Any change of the internal or external milieu may represent
a source of stress triggering a complex and coordinated set
of physiological responses involving (among others) the acti-
vation of the hypothalamus-pituitary-adrenal (HPA) axis [4–
6]. Although adaptive on the short run, prolonged exposure
to glucocorticoids hormones (GC), secreted following stress,
may exhaust the capacity of an organism to cope with further
stressors and, given the catabolic nature of these adrenal
glucocorticoids, lead to an impairment in brain plasticity
[5, 7, 8].
Stress begins in the brain with the perception and inter-
pretation of the stressful event and affects the brain itself as
well as the rest of the body through plastic changes, leading to
adaptation. The connection between central stress response
pathways and peripheral targets involves the alteration of a
number of neurochemical and/or inflammatory factors that
ultimately affect neuronal functioning and/or survival [8, 9].
One of the most representative players implicated in these
events is the neurotrophin brain-derived neurotrophic factor
(BDNF), which is involved in synaptic and morphological
plasticity of the brain both during development (with max-
imal levels during times of neuronal growth, differentiation
and synaptogenesis) as well as at adulthood [10–13]. High
levels of this neurotrophin are found in the hippocampus,
a brain region expressing also high levels of receptors for
GC (GR) and playing a main role in the negative feedback
regulation of the HPA axis, a pathway often disinhibited
in depressed subjects [14]. A growing body of evidence
shows that chronic stress decreases the expression of BDNF
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contributing to neuronal atrophy in the hippocampus and
that antidepressant treatment reverses or blocks these effects,
restoring brain plasticity [8, 9, 15, 16].
By being able to directly affect HPA axis activity [9,
17] and being produced by cells outside the nervous sys-
tem (including immune cells, adipocytes, endocrine, and
endothelial cells), BDNF has a key position in integrating
neural, immune, and endocrine responses to stress [8, 18, 19].
Indeed, the central nervous system and the immune system
are known to be engaged in an intense bidirectional crosstalk
which can be affected by stress and which involves multiple
mediators, including cytokines and growth factors [20]. As
an example, the immune signaling cytokines, particularly the
proinflammatory ones such as interleukin-6 (IL-6) or tumor
necrosis factor-alpha (TNF-𝛼), are elevated following stress
exposure and can thwart brain plasticity eliciting depressive
symptoms, which are amenable to antidepressant treatment
[20]. However, the directionality of the effects of stress is still
a matter of intense investigation: for instance, GC released
in response to stress can act both enhancing and inhibiting
immune responses and by decreasing or increasing levels of
neurotrophins [21–24]. Such opposite effects might coexist
in light of the fact that during stress, multiple interacting
mediators are activated in a nonlinear network influencing
different systems and functions [25]. Factors such as the
duration (acute versus chronic) of stress as well as the time
of exposure to GC, relative to the activation and time course
of the immune response, might differently impact health
outcome [21]. Progress in understanding the pathophysiology
of stress would greatly benefit from further preclinical studies
incorporating both the permissive as well as the inhibitory
role of GC in immune-endocrine interactions and mimic
conditions experienced in everyday life [26].
Restraint stress (RS) and the chronic disruption of the
social hierarchy (SS) are two of the most widely used
experimental paradigms that can induce stress in mice. The
first relies on a combination of psychological and physical
stimuli and is considered a reliable model of severe stress in
humans [27, 28]; the latter represents a comprehensive and
ethologically relevant paradigm inducing chronic stress and
leading to anxiety and/or depressive-like symptoms as often
reported in stress-precipitated major depression [29–31].
Thus, the main aim of the present study was to characterize
central and peripheral effects of different stressors, applied
for different time lengths on neuroendocrine and immune
responses in adult male C57BL/6J mice. Specifically, we
compared the effects of repeated (7 versus 21 days) RS and SS
on neuroendocrine (circulating corticosterone) and immune
(circulating cytokines and splenic apoptosis) function and on
a marker of brain plasticity (hippocampal BDNF) in order
to identify a specific neuroendocrine profile in response to
a selective type of stress.
2. Materials and Methods
2.1. Animals. Experimental subjects were adult male
C57BL/6J mice purchased from a commercial breeder
(Charles River, Calco, Italy). Upon arrival, all animals
were group-housed in the same room provided by air
conditioning (temperature 21 ± 1∘C, relative humidity
60 ± 10%), in transparent Plexiglas cages (29 cm × 12 cm ×
14 cm), under a reversed 12/12 h light/dark cycle with lights
off from 0800 to 2000 h. Pellet food (standard diet Altromin-
R, Rieper, Italy) and tap water were continuously available.
All stressors were administered randomly throughout
the active phase of the day. A Social Interaction Test was
used as a challenge to assess HPA axis response following
the social stress procedure and took place between 1700–
2000 h, that is, during the corticosterone (CORT) circadian
trough. All subjects were sacrificed at the end of the stress
procedure. Animal handling and experimental procedures
were performed in accordance with the EC guidelines
(EC Council Directive 86/609 1987) and with the Italian
legislation on animal experimentation (Decreto L.vo 116/92).
2.2. Experimental Procedures
2.2.1. Experiment I: Effects of Restraint Stress on Neuroen-
docrine and Immune Responses. Experimental subjects were
15 mice divided into three groups: 7 days restraint stress (RS7,
𝑛 = 5), 21 days restraint stress (RS21, 𝑛 = 5), and unhandled
controls (CTRL, 5 subjects left undisturbed in their home
cage). All subjects undergoing the same treatment condition
were group-housed. The restraint procedure consisted in
removing subjects from their home cage and putting each
of them in a conical 50mL falcon tube, provided with holes
for breathing, on a laboratory bench under dim light for
3 consecutive hrs/day. The stress was administered each
day at random times in order to prevent habituation to
the procedure. Animals from the RS21 were used to assess
stress-related changes in CORT levels so to have repeated
measures for each subject during days 1, 7, and 21. On
these days the procedure was administered at a fixed times
in order to take into account circadian rhythm, that is,
from 1700 to 2000. Blood samples were collected by tail
nick at 0 (basal) and 180min from the onset of stress (i.e.,
at 2000). At the end of stress all mice (CTRL, RS7, and
RS21) were sacrificed, trunk blood was collected to assess
levels of the proinflammatory cytokines interleukin 6 (IL-6)
and tumor necrosis factor-alpha (TNF-𝛼), and of the anti-
inflammatory cytokine Interleukin 10 (IL-10), [32, 33]. Brain
and spleen were dissected out in order to assess, respectively,
hippocampal BDNF levels and lymphocyte apoptosis.
2.2.2. Experiment II: Effects of Social Stress on Neuroendocrine
and Immune Responses. Experimental subjects were 48 adult
male mice divided into three groups: 7 days social stress (SS7,
𝑛 = 16), 21 days social stress (SS21, 𝑛 = 16), and controls
(CTRL, 16 subjects group-housed). All mice undergoing the
SS procedure were ear-marked and housed into 4 cages (4
mice/cage) and social structure was disrupted twice a week
for one or three weeks by replacing one mouse with a novel
unfamiliar selected randomly from another cage [34, 35].
Sawdust was replaced at the same time in all cages. Control
mice were also ear-marked and housed in stable groups of
4 mice/cage. Cages were cleaned and sawdust replaced twice
a week mimicking the handling procedure of the SS groups
[31].
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The activity of the HPA axis was assessed in response
to a 20-minute acute stress (Social Interaction Test) and
blood samples for CORT evaluation were collected from 8
subjects per group (CTRL, SS7, SS21) right before (basal) and
30min following the end of stress. Briefly, the night before the
Social Interaction Test, all subjects were individually housed
to stimulate social interactions [36–38]. On the day of test,
micewere placed in a novel cage, identical to the holding cage,
ideally subdivided in three equal parts, with an unfamiliar
conspecific of the same strain, weight, and sex that had been
previously isolated (standard opponent). Standard opponents
were marked with a yellow, scentless, and nontoxic paint [31].
At the end of the test mice that did not undergo the
Social Interaction test (5 mice for each group, randomly
chosen) were sacrificed, and trunk blood was collected to
assess also levels of IL-6, TNF-𝛼, and IL-10 [32, 33]. Brains
and spleen were dissected out, in order to assess, respectively,
hippocampal BDNF levels and lymphocyte apoptosis.
2.3. Radioimmunoassay for Corticosterone Determination-
RIA. Blood samples (100 𝜇L, approximate volume) were col-
lected individually in potassium EDTA coated tubes (1.6mg
EDTA/mL blood, Sarstedt, Germany). All samples were
kept on ice and later centrifuged at 3000 rpm for 15min
at +4∘C. Blood plasma was transferred to Eppendorf tubes
for CORT determination and stored at −20∘C until further
analysis. CORTwasmeasured using a commercially available
radioimmunoassay (RIA) kit containing 125Iodine-labeled
CORT; 5 𝜇L of plasma was sufficient to carry out CORT
measurement. Sensitivity of the assay was 0.125mg/dL, inter-
and intra-assay variationwas less than 10 and 5%, respectively
(MP Biomedicals Inc., CA, USA). Vials were counted for
2min in a gamma-scintillation counter (Packard Minaxi
Gamma counter, Series 5000).
2.4. BDNF Measurement. BDNF evaluation was carried out
with an enzyme-linked immunosorbent assay kit (BDNF
Emax ImmunoAssay System numberG7610, Promega,Madi-
son, Wisconsin, USA) following the instructions provided
by the manufacturer. Following sacrifice brains were quickly
removed and the hippocampus was dissected out and
immediately stored at −80∘C until used. Brain tissues were
homogenized in a lysis buffer and centrifuged at 14000 rpm,
and the supernatant was used for BDNF analyses. Briefly,
BDNF standard and brain samples were distributed in 96-
well immunoplates precoated with monoclonal anti-mouse
BDNF antibody (100mL/well) and incubated for 2 h at room
temperature. After washing, plates were incubated with an
anti-human BDNF antibody for 2 h at room temperature.The
plates werewashed again and then incubatedwith an anti-IgY
horseradish peroxidase (HRP) for 1 h at room temperature.
Tetramethylbenzidine (TMB)/peroxidase substrate solution
was added to the wells to produce colorimetric reaction
measured at 450 nm with a microplate reader (Dynatech MR
5000, Dynatech Laboratories, Chantilly, VA, USA). BDNF
concentrations were determined from the regression line for
the BDNF standard incubated under similar conditions in
each assay. The sensitivity of the assay was about 15 pg/mg
of BDNF, and the cross-reactivity with other related neu-
rotrophic factors (NGF, NT-3, and NT-4) is considered nil
[39].
2.5. Cytokines Determination. Quantitative evaluation of
TNF-𝛼, IL-6, and IL-10 in sera from trunk blood of stressed
and control mice was determined by ELISA kits (R&D
Systems, Inc., Minneapolis, USA) according to the manu-
facturer’s instructions. Briefly, standards, controls, and sera
were placed into the wells and incubated 2 h at room temper-
ature. After washing 5 times, the enzyme-linked polyclonal
antibody specific for mouse cytokines was added to the wells
and then, afterwashing, the substrate solutionwas added.The
enzyme reaction was read at 450 nm (correction wavelength
set at 570 nm). The samples values were read off the standard
value.
2.6. Splenocytes Apoptosis. Spleens were gently removed and
suspended in ice-cold culture RPMI-1640 medium (GIBCO
BRL, Grand Island, NY). Splenocytes were isolated frommice
spleen by flushing 5mL of RPMI-1640medium into spleen by
needle and syringe. Cells were then centrifugated at 1200 rpm
in order to remove cellular debris. Cells were resuspended in
supplemented RPMI 1640 and counted on a hemocytometer
in trypan blue to ensure viability. Average viability was >90%.
Splenocytes were then cultured in RPMI-1640 medium with
10% FBS (Euroclone, Pero, Italy), 2mM glutamine (Sigma, St
Louis, MO), and 50𝜇g/mL gentamycin (Sigma). Apoptosis
was measured after 1 h of culture. Apoptosis was quantified
using FITC-conjugated annexin V (AV) and propidium
iodide (PI) apoptosis detection kit (Marine Biological Lab-
oratory, Woods Hole, MA) according to the manufacturer’s
protocol. Reported data are referred to AV-positive apoptotic
cells. AV binds to phosphatidylserine which is exposed at
the outer surface of the cell membrane already at early
stages of apoptosis and remains so during the subsequent
process of apoptosis. By defining apoptotic cells as those cells
staining with AV, irrespective of PI staining, we were able to
detect early (AV+/PI− cells) as well as late (AV+/PI+ cells)
apoptotic cells. In this study, we analyzed specifically “early
apoptosis” in which the nuclear changes are observed first, in
contrast to the changes seen in the later stages of apoptosis
and then in the necrosis, which usually begin with cell
membrane damage [40, 41]. Acquisition was performed on
a FACSCalibur cytometer (BD Immunocytometry Systems)
and 50.000 events per sample were run. Data were analyzed
using the Cell Quest Pro (BD Immunocytometry Systems)
software.
2.7. Statistical Analysis. Data were analyzed using parametric
analysis of variance (ANOVA) with “condition” (control
and stress) as between-subjects factor (BDNF, cytokines,
apoptosis, CORT) and “day” (1, 7, 21) and “time” (0 and 180)
as within-subject repeated measures (CORT assessment only
for the restraint stress).Post hoc comparisonswere performed
using theTukey’s test. Statistical analysiswas performedusing
Statview II (Abacus Concepts, CA, USA). Data are expressed
as mean + SEM. A significance level of 0.05 was chosen.
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Figure 1: Effect of restraint stress on CORT secretion in mice. All subjects undergoing RS showed a reduced response of the HPA axis on
day 7 (a). Effect of social stress on CORT secretion in mice. The response to an acute challenge (represented by the Social Interaction Test)
was effective in inducing an increase in CORT secretion in all groups, with no differences in relation to social stress exposure (b). Results are
presented as mean + S.E.M. ∗𝑃 < 0.05.
3. Results
3.1. Experiment I: Restraint Stress
3.1.1. Corticosterone. Restraint stress was effective in chal-
lenging the HPA axis. In fact, RS subjects showed overall
higher CORT levels (main effect of condition: F(1,8) = 17.917,
𝑃 = 0.0029) compared to controls, particularly 180 minutes
from the onset of stress (interaction between condition and
time: F(1,8) = 12.022, 𝑃 = 0.0085). Moreover, a blunted HPA
axis response characterized RS subjects on day 7 (main effect
of days F(1,8) = 3.618 𝑃 = 0.0505; see Figure 1(a)).
3.1.2. BDNF. BDNF evaluation was performed on 4 mice in
each group since values from some subjects (1 subject for each
group)were found to be outliers andwere therefore discarded
from the analysis (Grubbs’ test performed by GraphPad
Software).
A time-dependent effect of RS was found for hippocam-
pal BDNF levels (see Figure 2). In particular, post hoc
comparisons show a decrease in BDNF levels following 21
days of RS compared to RS7 (main effect of condition F(2,9) =
4.164, 𝑃 = 0.0500). The latter group did not differ from the
CTRL subjects. However, it is worth noticing that the lack
of difference between these two groups might be related to
a reduced power of the statistical test (0.574) suggesting that
this result suffers from a low number of experimental subjects
(only 4 animals per experimental group) possibly masking
other significant trends (RS7 versus CTRL).
3.1.3. Cytokine Production. Following 7 days of restraint
stress a tendency to increase was observed for levels of IL-
6 (F(2,12) = 3.480; 𝑃 = 0.0643, Figure 3(a)). This trend
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Figure 2: Effects of restraint stress on hippocampal BDNF levels.
BDNF levels were decreased following a chronic 21 days restraint
procedure compared to 7 days of repeated restraint. Data shown are
mean + S.E.M. ∗𝑃 < 0.05.
reached statistical significance when assessing TNF-𝛼 (main
effect of condition: F(2,12) = 5.558; 𝑃 = 0.0196, Figure 3(b))
that returned to basal levels after 21 days. By contrast, IL-
10 increased only after 21 days of restraint (main effect of
treatment: F(2,12) = 5.345; 𝑃 = 0.0219, Figure 3(c)).
3.1.4. Splenocytes Apoptosis. Splenocytes apoptosis slightly
decreased after 21 days of restraint (main effect of condition:
F(2,12) = 8.597; 𝑃 = 0.0048, post hoc RS7 days versus RS21
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Figure 3: Effect of RS and SS on the immune system response. Restraint stress procedure. Following 7 days of restraint stress the
proinflammatory cytokine TNF-𝛼 increases, (b) while the increase in IL-6 during days 7 and 21 just missed statistical significance (a); by
contrast the anti-inflammatory cytokine IL-10 increased following 21 days (c). The percentage of apoptotic splenocytes was found to be
decreased following 21 days of stress (d). Social stress procedure. Levels of IL-10 were increased already after 7 days of the SS procedure (f).
Splenocytes apoptosis was increased after 7 days of SS and decreased following 21 days (g). No difference is evident as for levels of IL-6 (e).
Results are presented as mean + S.E.M. ∗∗𝑃 < 0.01, ∗𝑃 < 0.05.
days 𝑃 < 0.01; see Figure 3(d)). No difference was found
between CTRL and RS7.
3.2. Experiment II—Social Stress
3.2.1. Corticosterone. TheSocial Interaction Test was effective
in inducing the activation of the HPA axis in all groups,
regardless of their stress history (effect of social challenge:
F(1,29) = 153,515; 𝑃 < 0.0001, Figure 1(b)).
3.2.2. BDNF. Social stress, per se, did not affect hippocampal
BDNF levels (no main effect of condition: F(2,12) = 2.015 𝑃 =
0.1759, data not shown).
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3.2.3. Cytokine Production. Social condition did not affect
significantly the production of IL-6, even if a slight increase
after 7 days of social stress was observed, (effect of condition:
F(2,12) = 3.075 𝑃 = 0.0835, see Figure 3(e)). By contrast,
serum levels of IL-10 increased after 7 days of the social
stress procedure (main effect of condition: F(2,12) = 13.217
𝑃 = 0.0009, see Figure 3(f)). Differences in serum TNF
levels between control and social stressed mice appeared
undetectable (data not shown).
3.2.4. Splenocytes Apoptosis. Splenocytes apoptosis increased
after 7 days of social stress and decreased following 21 days
(main effect of treatment: F(2,12) = 47.932; 𝑃 < 0.0001, see
Figure 3(g)).
4. Discussion
Data from this study show that chronic RS is a powerful stres-
sor eliciting strong neuroendocrine, and immune responses
and that brief versus prolonged exposure to this stress results
in a differential activation of these systems in mice. In
addition, we were able to identify a specific neuroendocrine-
immune profile associated to specific changes in hippocam-
pal BDNF levels. Results suggest a fine modulation of the
crosstalk between central and peripheral pathways of adap-
tation and plasticity and that the length of stress exposure
is crucial to determine its final outcome on health or
disease.
Allostasis—or “stability through change”—is defined as
any neural, neuroendocrine and immune activation leading
to adaptation in the face of stressful challenges [4]. While
in the short run, activation of these systems is essential to
the maintenance of homeostasis and survival yet, over longer
time intervals, it imposes a cost-allostatic load—that can
accelerate disease processes or participate to pathological
changes associated, among others, to immunosuppression
[4]. When we studied the characteristics of the diverse
stressors applied for different lengths of times, we found that
upon prolonged exposure to RS (21 days), an increase in the
immunogenic/allostatic load was observed, mirrored by a
peak in CORT levels comparable to that observed on day 1.
This was associated to a suppression of the immune system
with decreased levels of the proinflammatory cytokine TNF-
𝛼 and increased levels of the anti-inflammatory cytokine IL-
10. In addition, a decrease in hippocampal BDNF levels was
found, suggesting a reduction in the ability to cope with
prolonged stress (brain plasticity).
Analyzing more in detail the effects of RS, we found
that, following 7 days of this procedure, CORT elevation
was significantly lower than on the first stimulation (day
1), suggesting an habituation of the system to the chronic
procedure, as previously shown [42]. This effect, which
appears to be mediated by limbic regions [8], is likely to
have consequences for the functioning of a number of GC-
sensitive systems, including the immune system. Indeed,
reduced CORT levels could disinhibit immune function,
leading to a proinflammatory response, as suggested by the
increase in the levels of TNF-𝛼.
A number of evidence support the hypothesis that a
moderate increase in the levels of proinflammatory cytokines,
such as TNF-𝛼, might result in an overall “priming effect”
on the immune system, leading to better abilities to cope
with further physiologic/stressful stimuli [21, 43–46]. Worth
noticing, the response to stress observed does not only
involve peripheral targets, but also extends to central medi-
ators. In fact, after 7 days of RS, hippocampal BDNF protein
levels showed a trend towards an increase, possibly reflecting
a neuroprotective mechanism. By contrast, after 21 days of
RS, BDNF levels were found to be decreased and this was
associated to an augmented anti-inflammatory response by
the immune systemwith increased IL-10 levels and a return of
TNF-𝛼 to basal levels. It must be emphasized that while acute
changes in BDNF levels might represent a coping response
to stressful events, and thus being beneficial, prolonged
exposure to stressors and increased allostatic load would lead
to detrimental effects as reduced BDNF signaling in the adult
brain may be involved in the pathophysiology of psychiatric
disorders [47–49].
A fine regulation of apoptosis might positively affect
optimal immune function. This is achieved by maintaining
lymphocyte homeostasis by a continuous removal of cells that
have been activated once they have served their function.
Therefore, inappropriate induction of such a mechanism
could result in a variety of pathological effects such as
autoimmune diseases, while the maintenance of physio-
logically regulated levels of apoptosis might exert a ben-
eficial/protective effect [50]. In this context, the observed
decrease in apoptosis levels following 21 days of RS, suggests
a long-term impairment of the immune system response.
Compared to RS, SS resulted in an overall lower response
of the HPA axis as well as of the immune system. Differ-
ences were both quantitative and qualitative. In particular,
no change in TNF-𝛼 could be detected, while an earlier
increase in IL-10 was observed compared to RS, suggesting
an anticipated anti-inflammatory reaction in response to this
specific stressor. Differently from RS data, splenic apoptosis
increased after 7 days of SS, suggesting that it might represent
a reliable early stress-sensitive physiological marker.
Taken together, data from this study clearly indicate a
differential role of psychophysical versus social and of brief
versus prolonged stress on neuroendocrine and immune
function suggesting that the quality and the extent of
the stress period are crucial in determining individual
neuroendocrine-immune responses to external challenges.
In addition, and more intriguingly, all these peripheral
responses were associated to specific changes in hippocampal
BDNF levels. We hypothesize that this neurotrophin might
represent a key modulator of neuro-immunoendocrine path-
ways, playing a pivotal role in the orchestration/maintenance
of the brain and peripheral plasticity leading to optimal
coping strategies to stressful events [8]. Future studies should
employ pharmacological challenges aimed at investigating
such interactions.
While this is a first attempt to mimic some of the
qualitative and temporal features of “stress,” studies are
ongoing to extend the range of mediators analyzed and
the peripheral targets, to evaluate more extensively the role
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of acute versus chronic stressors on neuroendocrine and
immune function. In addition a thorough characterization
of the specific changes occurring in brain plasticity in other
regions involved in neuroendocrine-immune integration will
help elucidating the mechanisms underlying the benefi-
cial/pathological effects of stress increasing the translational
value of these studies.
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